Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0R2ZG
|
|||
Former ID |
DNC008910
|
|||
Drug Name |
[Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C150H226N40O47
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N
|
|||
InChI |
1S/C150H226N40O47/c1-16-77(10)121(147(235)168-80(13)126(214)176-104(59-86-62-159-91-35-24-23-34-89(86)91)137(225)178-100(55-74(4)5)138(226)187-119(75(6)7)145(233)175-93(36-25-27-51-151)129(217)161-65-111(199)169-92(38-29-53-158-150(155)156)128(216)164-68-118(210)211)189-139(227)102(56-83-30-19-17-20-31-83)179-134(222)98(46-50-116(206)207)174-133(221)94(37-26-28-52-152)172-125(213)79(12)166-124(212)78(11)167-132(220)97(43-47-109(154)197)171-112(200)66-162-131(219)96(45-49-115(204)205)173-135(223)99(54-73(2)3)177-136(224)101(58-85-39-41-88(196)42-40-85)180-142(230)106(69-191)183-144(232)108(71-193)184-146(234)120(76(8)9)188-141(229)105(61-117(208)209)181-143(231)107(70-192)185-149(237)123(82(15)195)190-140(228)103(57-84-32-21-18-22-33-84)182-148(236)122(81(14)194)186-113(201)67-163-130(218)95(44-48-114(202)203)170-110(198)64-160-127(215)90(153)60-87-63-157-72-165-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,159,191-196H,16,25-29,36-38,43-61,64-71,151-153H2,1-15H3,(H2,154,197)(H,157,165)(H,160,215)(H,161,217)(H,162,219)(H,163,218)(H,164,216)(H,166,212)(H,167,220)(H,168,235)(H,169,199)(H,170,198)(H,171,200)(H,172,213)(H,173,223)(H,174,221)(H,175,233)(H,176,214)(H,177,224)(H,178,225)(H,179,222)(H,180,230)(H,181,231)(H,182,236)(H,183,232)(H,184,234)(H,185,237)(H,186,201)(H,187,226)(H,188,229)(H,189,227)(H,190,228)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,155,156,158)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
|
|||
InChIKey |
XXYMTCGQDUSUOO-RHBBJNDVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.